The hepatitis b treatment market is expected to reach USD 129.40 Billion by 2032 at 4.5% CAGR during the forecast period 2023-2032.
The viral infection is caused by Hepatitis A, B or C virus which causes liver infection leading to liver damage. Hepatitis B virus can transmit in contact with infected blood, by consumption of contaminated water, and by using infected needles. Some of the major symptoms are weakness, jaundice, poor appetite, dark-coloured urine, skin itching, leg swelling, weight loss, drowsiness and others. The rise in concern for a better treatment for Hepatitis B is boosting the market at the global level.
The availability of hepatitis B treatment and the awareness of hepatitis B infections will significantly drive the market in the forecast period. The concern and reasonable treatment are the two growth factors that highly accelerate the market’s growth. The advancement in the development of new treatments and medications with a higher success rate will lead the market towards greater opportunities. The continuous development of drugs and vaccines for hepatitis B treatment is aiding the market. AIDS survivors with haemodialysis and immunosuppressants are propelling the market’s growth in the forecast period.
NPO Microgen, a division of Nacimbio Holding, obtained a certificate of marketing authorization for a hepatitis B medicinal medication in 2023. The medication has a good level of safety and tolerability, according to clinical trials. The medication is now the first intravenous specific immunoglobulin for the protection of hepatitis B in both adults and children in Russia. Antigen-Neo is a medication that has been approved to prevent hepatitis B in both adults and children, including hepatitis B caused by pregnant women who test positive for the surface antigen.
Following five years of experience in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced today, 2023, that HULIO® injectable, a biosimilar of Humira®, is now available to patients in the United States. Several biosimilar approvals have been obtained by Biocon Biologics, which recently announced that it has acquired Viatris' global biosimilars business. These approvals have been obtained in the United States, Europe, and more than 100 other countries. Biocon Biologics is now able to assist in offering patients and medical professionals more accessible and inexpensive therapy alternatives in the immunology, diabetes, and cancer therapeutic areas thanks to the acquisition of Viatris' biosimilars company.
In November 2022, the U.S. Food and Drug Administration approved Gilead Sciences Inc’s sNDA for sNDAVemlidy (tenofovir alafenamide) 25 mg tablets daily to treat children with chronic hepatitis B virus (HBV) infection aged 12 and above having compensated liver disease. In April, Gilead Sciences Inc. said that it had obtained FDA approval for its new drug application for Veklury (remdesivir) as a treatment for COVID-19 in pediatrics over four weeks of age who weigh at least three kilograms. This condition makes sufferers of mild COVID-19 cases or those with this illness more likely to be hospitalized or die from it than any other category of people. For non-hospitalized adults and adolescents suffering from severe COVID-19, this is the first antiviral therapy authorized via the sNDA process on Veklury.
Gilead Sciences Inc. reported that the U.S. Food and Drug Administration had given supplemental new drug application to Vemlidy (tenofovir alafenamide), capsules dosed once daily at 25 mg in chronic hepatitis B infections among patients ≥6 years old weighing ≥25 kg with compensated liver disease in March 2024.
Starting in February 2024, TherVacB began its first clinical testing as an innovative approach aimed at vaccine therapy for treating chronic hepatitis B. It was designed under the guidance of Helmholtz Munich. For instance, it is supposed to provide a curative measure by boosting individual natural defense systems against pathogens from the aforementioned parasite.
According to GSK’s announcement in February 2024, bepirovirsen has obtained Fast Track designation from the U.S. FDA for treating chronic hepatitis B. This not only reduces viral DNA synthesis and Hepatitis B surface antigen levels in the blood but also increases immunity with improved possibilities of long-lived responses.
Chula researchers have made a new wireless one-step hepatitis B virus test kit that detects infections and sends the data online by February 2024. The antigen-antibody interaction concept is used by novel diagnostic kits to detect Hepatitis B surface antigen (HBsAg) through electrochemical biosensors.
The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic.
On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others.
By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.
Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Some of the key players in the hepatitis B treatment market are
The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.
Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.
Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.
On the other hand, the Middle East and Africa hold the least share in the hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region.
Hepatitis B Treatment Market Segmentation
Hepatitis B Treatment Type Outlook
Acute
Chronic
Hepatitis B Treatment Treatment Outlook
Immune Modulator Drugs
Pegylated Interferon
Interferon Alpha
Antiviral Drugs
Tenofovir disoproxil
Entecavir
Telbivudine
Lamivudine
Others
Vaccine
Surgery (Liver Transplant)
Hepatitis B Treatment Distribution Channel Outlook
Hepatitis B Treatment Market Key Players
Recent Development
April 2022: Gilead Sciences, Inc. has declared that U.S. Food and Drug Administration (FDA) approved its new drug application (sNDA) for Veklury (remdesivir) for pediatric patients treatment older than 28 days, weighing 3 kg. Patients with COVID-19 or moderate COVID-19 are considered at high risk for progression hospitalization or death. This approval for sNDA follows Veklury non-hospitalized adult and adolescent patients treated at high risk of severe COVID-19.
April 2022: Antios Therapeutics, Inc, a global clinical-stage biopharmaceutical company that has developed advanced therapies for the treatment of chronic hepatitis B virus. It has recently been announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Phosphoramidates for Hepatitis B Virus treatment. The compositions contain Antios' novel Active Site Polymerase Inhibitor Nucleotide), ATI-2173, along with other therapies and mechanisms.
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USD 129.40 Billion |
| Â Â CAGR | Â Â 4.5% |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Treatment, Distribution channel |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Growing geriatric population· Increasing the prevalence of viral infection· Growing sexually transmitted diseases |
Hepatitis B Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
Hepatitis B Treatment Market is expected to exhibit a strong 4.5% CAGR over the forecast period from 2023 to 2032.
The rising prevalence of hepatitis B is the major driver for the market.
The risk of side effects from hepatitis B therapeutics is the key restraint on the global hepatitis B treatment market.
The Americas dominates the global hepatitis B treatment market.
Leading players in the hepatitis B treatment market include Accord Healthcare, Bristol-Myers Squibb, Apotex, Aurobindo Pharma, and Merck, among others.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
